Teclistamab 30mg/3ml solution for injection vials

B-cell maturation antigen (BCMA) is a member of the tumour necrosis factor family of receptors [A253587] expressed on the surface of B-lineage cells, as well as late-stage B cells and plasma cells.[L43597][L43622] BCMA interacts with its ligands to activate survival signalling pathways such as NF-kappa B, STAT3, ERK1/2, and AKT/PI3K,[A253672] and upregulates anti-apoptotic proteins to regulate B-cell maturation, proliferation, and survival.[A253587] Besides B cells, BCMA is also widely expressed on multiple myeloma (MM) cells and supports the survival of MM cells, making it a promising therapeutic target for therapeutic agents for MM.[A253587][A253672][A253677]

Teclistamab is a bispecific T cell engaging antibody that targets the CD3 receptor, which is expressed on the surface of T cells, and BCMA, which is expressed on malignant cells. Due to its dual binding sites, teclistamab is able to draw CD3⁺ T cells in close proximity to BCMA⁺ cells, resulting in T cell activation and T cell-mediated cytotoxicity, which is mediated by secreted perforin and various granzymes stored in the secretory vesicles of cytotoxic T cells.[L43597] This effect occurs without regard to T cell receptor specificity or reliance on major histocompatibility complex (MHC) Class 1 molecules on the surface of antigen presenting cells.[L43597] Ultimately, teclistamab promotes the lysis and death of BCMA⁺ cells.[L43597][L43622]